Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Nitric Oxide : Biology and Chemistry|July 16, 2011
A cross-sectional evaluation of seasonality as a determinant of endothelial functionY R Patel, K A Han, A A Lteif, et al.
The Journal of Investigative Dermatology|October 1, 1993
7,12-Dimethylbenz[a]anthracene-induced mouse keratinocyte malignant transformation independent of Harvey ras activationB L Schneider, G T Bowden, C Sutter, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 21, 2010
The effects of total energy expenditure from all levels of physical activity vs. physical activity energy expenditure from moderate-to-vigorous activity on visceral fat and insulin sensitivity in obese Type 2 diabetic womenB K Koo, K A Han, H J Ahn, et al.
The Journal of International Medical Research|September 8, 2010
Resistance exercise did not alter intramuscular adipose tissue but reduced retinol-binding protein-4 concentration in individuals with type 2 diabetes mellitusY H Ku, K A Han, H Ahn, et al.
Genes, Brain, and Behavior|September 14, 2017
The mushroom body D1 dopamine receptor controls innate courtship driveJ Lim, A I Fernandez, S J Hinojos, et al.
The Journal of International Medical Research|March 18, 2010
Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertensionJ-M Lee, J-H Kim, H-S Son, et al.
Diabetes, Obesity & Metabolism|January 11, 2016
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialS Hong, C-Y Park, K A Han, et al.
Diabetes, Obesity & Metabolism|December 6, 2014
Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trialM K Kim, E-J Rhee, K A Han, et al.
Pageof 2